BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £273.0m
Enterprise Value £139.6m
Revenue £11.6m
Position in Universe th / 1832

BRIEF-Bioinvent Streamlines Agreement On Anti-Fcγrllb Antibody

Mon 11th January, 2021 7:16am
Jan 11 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT STREAMLINES AGREEMENT ON ANTI-FCΓRLLB ANTIBODY,
BI-1206, AHEAD OF PHASE I/II DATA
    * HAS RESTRUCTURED A CLINICAL DEVELOPMENT AGREEMENT WITH
CANCER
RESEARCH UK (CRUK), WORLD'S LEADING CANCER CHARITY, FOR ITS
UNIQUE ANTI-FCΓRIIB ANTIBODY, BI-1206
    * IN EXCHANGE FOR A ONE-TIME PAYMENT, REVISED DEAL
SIMPLIFIES AND
REDUCES BIOINVENT'S OBLIGATIONS TO CRUK, WHICH PROVIDES
BIOINVENT WITH MORE FLEXIBILITY TO CARRY OUT DEVELOPMENT AND
PARTNERING ACTIVITIES WITH BI-1206
    * RESTRUCTURED AGREEMENT WITH CRUK RELEASES BIOINVENT FROM
OBLIGATIONS TO PAY DEVELOPMENT OR COMMERCIAL MILESTONES TO CRUK
ON BI-1206 AND REDUCES ROYALTIES DUE ON NET SALES TO LOW SINGLE
DIGIT LEVELS
    * BIOINVENT WILL MAKE A ONE-TIME PAYMENT OF £2.5 MILLION TO
CRUK.
    * EARLY RESULTS FROM PHASE I OPEN LABEL STUDY IN NHL ARE
EXPECTED
IN EARLY 2021.

Source text for Eikon:  ID:nWkr8dmdpq 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.